纳米羟基磷灰石复合材料在癌症治疗中的应用进展

Abstract
Figure/Table
References
Related Citation (15)

Download:

Full Text ( PDF ) (2110KB)
Export: BibTeX | EndNote (RIS)

Abstract Hydroxyapatite (HAP) is the main inorganic component of human bones and teeth.With the excellent biocompatibility and bioactivity, it is widely used as a substitute for bone, and also widely used in biomedicine, coating materials, sewage treatment and other fields. Relevant studies have shown that HAP nanoparticles and HAP based nanocomposites can selectively inhibit the growth of cancer cells, and their anti-tumor properties have attracted many scholarś attention.Compared with traditional HAP particles, nano HAP has high specific surface area, high surface energy and targeting property. At the same time, it has high surface roughness and strong affinity, so it is easier to adsorb protein and shows better biocompatibility. However, the conventional nano hydroxyapatite is unstable and easy to agglomerate in vivo, which leads to the problems of large particle size and uneven distribution. There are still great obstacles in clinical application. The preparation of HAP nanocomposite system can improve its adaptability in vivo. The structure and properties of HAP particles, as well as the mechanism and characteristics of HAP particles in cancer treatment were introduced. The application of HAP nanoparticles based complexes in cancer treatment, including HAP composite scaffold, HAP nanocomposites by cross-linking technology, layer by layer self-assembly HAP capsules, hybrid HAP nanoparticles and active targeting HAP nanocomposites, were reviewed. At the same time, the existing problems in the application of nano HAP in cancer treatment were analyzed, and its future development trend was prospected, so as to provide a reference for the preparation of a new treatment system integrating tumor diagnosis, treatment and postoperative repair.

Key words： hydroxyapatite nanoparticles composites cancer therapy

Published: 08 January 2021

CLC number:

R318.08

Fund:This work was financially supported by the National Natural Science Foundation of China (81503020, 31600764), Scientific Research Funding Project of Liaoning Provincial Education Department (2019LJC04) and the Guidance Plan of Natural Science Foundation of Liaoning Province (2019-ZD-0459), Innovation and Entrepreneurship Training Program of Shenyang Pharmaceutical University (202010163026).

About author:: Xin Shen graduated from Shenyang Pharmaceutical University and received her B.S. degree in July 2020. Her research focuses on new biomedical materials.Yu Pang, an undergraduate in Shenyang Pharmaceutical University, her research focuses on new biomedical materials.He Lian obtained her Ph.D. degree in pharmaceutics from Shenyang Pharmaceutical University in 2014, and is now an associate professor in biomedical materials department of medical device college. Her research directions include bioactive materials and novel nanodrug delivery systems. As the project leader, she presided over one project of National Natural Science Foundation, one project of Liaoning Provincial Natural Science Foundation, one project of Liaoning Provincial Department of education, and one special research fund of Shenyang Pharmaceutical University. At present, she has obtained 2 authorized patents and published more than 20 papers in SCI journals, such as Mat. Sci. Eng C, J. Contrl. Res, Mol. Pharm, Colloids Surf. B, Biomaterial Science, Macromol. Biosci, et al.These anthors contributed equally to this work.

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	申欣
	孟昭旭
	廉鹤

Cite this article:

申欣,孟昭旭,廉鹤. Application Progress of Nano Hydroxyapatite Composites in Cancer Treatment[J]. Materials Reports, 2020, 34(Z2): 88-90.

URL:

http://www.mater-rep.com/EN/ OR http://www.mater-rep.com/EN/Y2020/V34/IZ2/88

1 毛春玲, 刘雅茹, 吴孟霏, 等. 化学试剂, 2020, 42(6), 699.
2 田家明, 张波, 李苏, 等. 辽宁化工, 2009, 38(11), 828.
3 林敬轶.中国新通信, 2019, 21(3), 243.
4 王志新,刘莹, 杨晓民. 中国老年学杂志, 2007, 27(23), 2276.
5 唐胜利, 袁媛, 刘志苏, 等.肝脏, 2003, 8(1), 21.
6 王芊, 曹晶晶, 王宏刚, 等.现代肿瘤医学, 2020, 28(4), 530.
7 Qing F, Wang Z, Hong Y, et al.Journal of Materials Science-Materials in Medicine, 2012, 3(9), 2245.
8 欧阳晨曦, 陈道达, 冯凌云, 等.华中科技大学学报(医学版), 2006, 35(3), 354.
9 冯凌云, 李世普, 陈闻杰, 等. 中国有色金属学报, 1999(3), 651.
10 陈超, 王慧明. 实用肿瘤杂志, 2003(6), 459.
11 Hou C H, Hou S M, Hsueh Y S, et al.Biomaterials, 2009, 30, 3956.
12 Ye F, Guo H F, Zhang H J, He X L. Acta Biomaterialia, 2010, 6(6), 221.
13 董文韬, 陈侃, 李善高, 等. 浙江理工大学学报(自然科学版), 2017, 37(5), 727.
14 杨联军, 荣子杰, 张赞杰, 等.中国临床解剖学杂志, 2014, 32(5), 585.
15 邹清霞. 微纳结构HA/PDA/CMCS双功能复合支架的制备及其抗肿瘤和促成骨分化性能研究. 硕士学位论文, 华南理工大学, 2019.
16 罗诗裕. 具有光热效应的顺铂-PHA复合材料的抗肿瘤基础研究.硕士学位论文, 成都医学院, 2019.
17 朱潇依. NIR/pH响应羟基磷灰石基杂化微囊的自组装构筑及智能药物释放.硕士学位论文, 郑州大学, 2019.
18 李淼. 微量元素掺杂羟基磷灰石的制备及生物学效应研究.硕士学位论文, 上海师范大学, 2019.
19 马晓雨, 刘永佳, 朱邦尚. 无机化学学报, 2018, 34(5), 917.
20 Heng C, Zhou X, Zheng X, et al. Materials Science and Engineering:C, 2018, 91, 556.
21 李大龙. 介孔磷灰石基纳米药物控制释放体系的构建与生物学评价. 博士学位论文, 哈尔滨工业大学, 2017.